Subscribe to Newsletter
Subspecialties Professional Development, Retina

Not All Big Pharma Loves Ophtho

In recent issues we’ve reported on the increasing number of the liaisons between the pharmaceutical industry and ophthalmology. But it’s not all plain sailing. Lpath, a San Diego, California-based biotech firm is currently developing a therapy for wet age-related macular degeneration (AMD) called iSONEP. Pfizer had an exclusive option for a worldwide license to develop and commercialize iSONEP but Lpath recently received notification that the world’s biggest pharmaceutical company wants to divest its commercial interests in ophthalmology, including its exclusive option on iSONEP.

Why might Pfizer be withdrawing from ophthalmology? Eight years ago, the company had petaganib (Macugen), the first anti-VEGF therapy to be approved by the FDA for the treatment of wet AMD. They had a thriving ophthalmology section to support, develop and market their groundbreaking drug. Then Genentech/ Novartis brought out ranibizumab. Petaganib slowed VA decline in patients, but could not stop it. When used appropriately, ranibizumab could, and so Pfizer saw its drug’s market share drop into single digit percentages. Was this the turning point that dulled the luster of ophthalmology for Pfizer?

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Mark Hillen

I spent seven years as a medical writer, writing primary and review manuscripts, congress presentations and marketing materials for numerous – and mostly German – pharmaceutical companies. Prior to my adventures in medical communications, I was a Wellcome Trust PhD student at the University of Edinburgh.

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Here
Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: